A Study of Remote Asthma Management Using an Integrated Artificial Intelligence-assisted Mobile Device Compared with Usual Asthma Care to Treat 6-17 Year Old Patients

Overview

About this study

This is a Decentralized Study, which means that for some, or all of the study visits, participants do not have to travel to a Mayo Clinic location.

The purpose of the study is to investigate clinician, adolescent participant, and caregiver satisfaction and effectiveness (non-inferiority) of remote asthma management at home with A-GPS and AT compared with usual asthma care in pediatric participants from 6-17 years of age with active asthma.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Clinician participants are eligible to be included in the study only if all of the following criteria apply:

  • Employed as a Community Pediatric and Adolescent Medicine clinician (consultant or nurse practitioner) at MCR downtown or MCHS Albert Lea/Austin/Red Wing.
  • Able to provide written consent.
  • Are willing to follow recommendations to schedule/see participant and their caregiver for regular asthma follow-up care every 3-6 months.
    • Note: Asthma care coordinators who are involved in the usual care of the pediatric participant will also be included in the study.

Pediatric participants are eligible to be included in the study only if all of the following criteria apply:

  • Ages 6-17 years old with diagnosis of asthma.
  • Have a caregiver who is willing to participate alongside pediatric participant and to have regular asthma follow-up care every 3-6 months.
  • Adolescent participants ages 13-17 years and their caregivers are able to give written informed consent; or child participants ages 8-12 years are able to provide assent and their caregivers are able to give written informed consent.
  • Both participant and caregiver are able to read and write in English.
  • Receive pediatric primary care at MCR or MCHS from participating study clinician.
  • Access for caregiver and/or adolescent participants to an Android or iPhone with Wi-Fi access and availability for at least monthly use.
  • Active asthma defined by at least one clinic visit with a diagnosis of asthma per Mayo EHR or on active asthma control or rescue medication in the past 12 months. Priority will be given to those with persistent asthma on inhaled corticosteroids therapy or those with poorly controlled asthma defined by any of the following criteria in the past 12 months, except item v (past 2-week period);
    • Asthma Control Test15 for adolescents ≥ 12 years or Childhood Asthma Control Test16 for children < 12 years (score< 20);
    • ED visit for asthma; or
    • Hospitalization for asthma; or
    • Unscheduled outpatient visit for asthma requiring oral corticosteroid use; or
    • Asthma symptoms at the screening interview, including 1) more than 2 days per week shortness of breath, wheezing, chest tightness, or 2) more than 1 night awakening due to asthma in the past 2-week period.
  • Participant had their latest asthma follow-up visit more than 3 months prior to the screening date of the study.

Exclusion Criteria:

Pediatric participants who do not meet the eligibility criteria described above will be excluded and those will be excluded from the study if any of the following criteria apply:

  • Major medical problems prohibiting study participation and inability to perform study procedures (including spirometry); suspected symptoms of exercise-induced laryngeal obstruction (EILO), tracheobronchial foreign body at or about the incidence date of asthma, wheezing occurring only in response to anesthesia or medications, bullous emphysema or pulmonary fibrosis on chest radiograph, PiZZ alpha1-antitrypsin, cystic fibrosis, or other major chest disease such as severe kyphoscoliosis or bronchiectasis.
  • Pediatric participant pregnancy.
  • Hyposensitization therapy for > 3 months prior to study enrollment.
  • Participation in any other interventional studies for asthma within 1 month prior to study.

Eligibility last updated 2/8/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Young Juhn, M.D., M.P.H.

Open for enrollment

Contact information:

Cures at Home

(904) 953-0816

curesathome@mayo.edu

More information

Publications

Publications are currently not available